United Therapeutics (NASDAQ: UTHR) appoints Victor Dzau to board
Rhea-AI Filing Summary
United Therapeutics Corporation appointed Victor Dzau, M.D. to its Board of Directors on July 22, 2026 and increased the Board size to 13 members, following a recommendation from the Nominating and Governance Committee.
Upon joining, Dr. Dzau received equity awards under the 2026 Stock Incentive Plan, consisting of an initial grant of 380 restricted stock units and 1,190 stock options, plus pro-rata grants of 350 restricted stock units and 1,110 stock options for the remainder of the 2026-2027 Board service year. He will initially serve without committee assignments, be compensated under the standard non-employee director program, and be covered by the company’s standard director indemnification agreement.
The company states that there are no transactions over $120,000 involving Dr. Dzau that would constitute related-party dealings and describes his addition as part of an ongoing Board refreshment effort aligned with its public benefit mission in rare diseases and transplantable organ technologies.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
restricted stock units financial
stock options financial
public benefit corporation regulatory
forward-looking statements regulatory
Board refreshment other
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What change did United Therapeutics (UTHR) make to its Board on July 22, 2026?
What equity compensation did Victor Dzau receive from United Therapeutics (UTHR)?
Will Victor Dzau serve on any United Therapeutics (UTHR) Board committees initially?
How does Victor Dzau’s appointment align with United Therapeutics (UTHR)’s mission?
Under what plans and agreements will Victor Dzau serve United Therapeutics (UTHR)?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other | (Commission | (I.R.S. Employer | ||
| Jurisdiction of | File Number) | Identification Number) | ||
| Incorporation) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On July 22, 2026, the Board of Directors (the Board) of United Therapeutics Corporation (the Company), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board. The Board determined that Dr. Dzau will not serve on a Board committee initially.
There is no arrangement or understanding between Dr. Dzau and any other persons pursuant to which he was selected as a director of the Company. Since the beginning of the Company’s last fiscal year through the present, there have been no transactions with the Company, and there are currently no proposed transactions with the Company, in which the amount involved exceeds $120,000 and in which Dr. Dzau had or will have a direct or indirect material interest within the meaning of Item 404(a) of Regulation S-K.
In connection with Dr. Dzau’s appointment to the Board, the Company awarded him the following awards under the Company’s 2026 Stock Incentive Plan: (a) 380 restricted stock units and 1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. These awards were granted on July 22, 2026, in accordance with the Company’s standard non-employee director compensation program (the Director Compensation Program), as described in the Company’s definitive proxy statement for its 2026 annual meeting of shareholders, filed with the Securities and Exchange Commission (SEC) on April 29, 2026. Dr. Dzau will be provided further compensation for his services in accordance with the Director Compensation Program. Dr. Dzau and the Company also entered into the Company’s standard indemnification agreement for directors and executive officers, effective July 22, 2026, the form of which was filed with the SEC as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 1, 2021.
| Item 7.01. | Regulation FD Disclosure. |
A copy of the press release announcing Dr. Dzau’s appointment is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act as amended, regardless of any general incorporation language in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description of Exhibit |
| 99.1 | Press Release dated July 23, 2026 |
| 104 | Cover page Interactive Data File - the cover page XBRL tags are embedded within the inline XBRL document. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UNITED THERAPEUTICS CORPORATION | ||
| Dated: July 23, 2026 | By: | /s/ Paul A. Mahon |
| Name: | Paul A. Mahon | |
| Title: | General Counsel | |
3
Exhibit 99.1
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
 |
SILVER SPRING, Md. and DURHAM, N.C., July 23, 2026 — United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026.
Dr. Dzau recently completed a 12-year tenure as President of the National Academy of Medicine (NAM) and formerly served as Chancellor for Health Affairs at Duke University, President and CEO of the Duke University Health System, and Chairman of Medicine at Harvard and Stanford Universities. His term with NAM expired at the end of June 2026, and in July 2026 he returned to Duke University as James B. Duke Distinguished Professor of Medicine, Chancellor Emeritus for Health Affairs, and Director of the Mandel Center. He also serves as Co-Chair of the G20 High-Level Independent Panel on Financing Pandemic Preparedness and Response. |
He is recognized globally for a highly decorated career as a physician-scientist and leader. His research laid the foundation for lifesaving drugs known as ACE inhibitors. He pioneered gene therapy for vascular disease and is now studying cardiac regeneration.
“Dr. Dzau is a visionary healthcare leader, with a storied career both nationally and internationally. I am honored he has joined our Board, and believe he is uniquely capable of guiding United Therapeutics in our public benefit mission of developing transplantable organs and organ alternatives for patients suffering from many forms of end-stage organ failure,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.
“I have admired United Therapeutics’ mission and progress over its 30-year history, and am thrilled to join its Board of Directors at one of the company’s most exciting moments. I look forward to supporting United Therapeutics as it pursues groundbreaking treatments for rare diseases and the bold mission of pioneering biomedical and bioengineering breakthroughs to help address the severe shortage of transplantable organs,” said Dr. Dzau.
“I am excited to add Dr. Dzau’s voice to our boardroom, and look forward to benefiting from his deep knowledge, experience, and insights in our industry and the healthcare system as a whole,” said Christopher Causey, Chairperson of the Nominating and Governance Committee of United Therapeutics’ Board of Directors. “Dr. Dzau’s addition to our Board is the latest step in our concerted Board refreshment effort, as we work to provide oversight and support of a company working on transforming patient care.”
About United Therapeutics
Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding our public benefit mission of developing transplantable organs and organ alternatives for patients suffering from many forms of end-stage organ failure, our ongoing Board refreshment efforts, the anticipated contributions of Dr. Dzau to our Board, our pursuit of groundbreaking treatments for rare diseases, our mission of pioneering biomedical and bioengineering breakthroughs to address the severe shortage of transplantable organs, our efforts to transform patient care, our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 23, 2026, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events or any other reason.
For Further Information Contact:
Investor Inquiries
https://ir.unither.com/contact-ir
Media Inquiries
communications@unither.com